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OBJECTIVES: Poor glycaemic control during pregnancy in
women with type 1 diabetes is associated with high risk of
pre-term delivery, neonatal mortality and morbidity. Improving
control might improve outcomes and reduce the cost of manag-
ing pre-term infants. This study assessed costs and outcomes
associated with insulin aspart (IAsp) and human insulin (HI) in
pregnant women with type 1 diabetes. METHODS: Women with
type 1 diabetes were enrolled if 10 weeks pregnant or planning
to become pregnant, and had HbA1C 8% at conﬁrmation of
pregnancy. Subjects were randomised to treatment with IAsp or
HI in a basal-bolus regimen with NPH insulin, with doses
titrated to American Diabetes Association guidelines. The effec-
tiveness endpoint in this analysis was the percentage of women
with a live birth at term (37 weeks gestation). We considered
costs of insulin and of inpatient care for pre-term infants. Length
of stay in intensive care was estimated from gestational age.
Costs were calculated from the perspective of the UK National
Health Service. Non-parametric bootstrapping was used to
generate conﬁdence intervals. RESULTS: Of 417 women ran-
domised, 322 became pregnant and effectiveness was evaluable
for 302, 151 in each arm. Signiﬁcantly more women experienced
a live birth at term with IAsp (72.8%) than with HI (60.9%),
difference 11.9% (95% CI 0.7%, 22.5%). Mean cost per woman
was £3347 for HI, and £3359 for IAsp, difference £13 (95% CI
-£612, £966). Insulin accounted for 9.7% of costs for IAsp and
5.6% for HI. The incremental cost-effectiveness ratio was £106
per additional live birth at term (95% CI dominant, £58076).
CONCLUSION: IAsp was associated with a signiﬁcantly higher
proportion of live births at term than HI. The cost of managing
pre-term births was large compared to the cost of insulin
administered.
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OBJECTIVES: Type 2 diabetes patients treated with human
premix insulin (with or without conventional oral antidiabetic
agents) were converted to biphasic insulin aspart 30 (BIAsp 30)
in PRESENT, a single-arm observational study conducted in
China (n = 2289). Patients showed a reduction in HbA1c of
1.82% points and reduced rates of hypoglycemic events (1576 to
476 per 100 patient years) three months after therapy conver-
sion. METHODS: A published and validated computer simula-
tion model of diabetes (CORE Diabetes Model) was used to
project short-term results obtained from PRESENT to estimate
long-term clinical and cost outcomes for patients switching from
human premix insulin to BIAsp 30 in a Chinese setting. Chinese
patient characteristics and mortality were derived from published
sources and primary research was performed to estimate costs of
treating complications and management practices in a Chinese
setting. Probabilities of complications were derived from land-
mark clinical and epidemiological studies. Total direct costs
(complications + treatment costs) were projected over patient
lifetimes for BIAsp 30 and current standard practice (baseline
values). Future costs and clinical beneﬁts were discounted at 3%
annually. RESULTS: Short-term therapy beneﬁts associated
with BIAsp 30 versus human premix (improvement in HbA1c
levels and a decrease in hypoglycemic events) were projected
to increase life expectancy by 0.632 years and improve
quality-adjusted life expectancy by 1.022 quality-adjusted life
years (QALYs) (7.664  0.111 versus 6.641  0.092 QALYs).
BIAsp 30 reduced total direct costs by RMB 7,484 (RMB
230,926  4,676 versus RMB 238,410  4,970) due to decreas-
ing the cost of treating diabetes-related complications (RMB
118,936 versus 147,449). CONCLUSION: The results indicated
that BIAsp 30 is dominant (less cost with more health beneﬁt)
versus human premix in the treatment of type 2 diabetes patient
in a Chinese setting, with lower direct costs and superior patient
outcomes due to reductions in diabetic-related complications.
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OBJECTIVES: The aim of this health economic study was
to assess the cost-effectiveness of acarbose versus placebo in
patients with Impaired Glucose Tolerance (IGT), based on the
ﬁndings of the STOP-NIDDM trial, in the South Korean setting.
METHODS: The CORE Diabetes Prevention Program, a peer-
reviewed and published computer simulation model, was used to
project long-term clinical and cost outcomes in type 2 diabetes
patients receiving acarbose or placebo. Transition probabilities,
risk adjustments, treatment effects and baseline cohort charac-
teristics were based on the STOP-NIDDM trial. Direct costs were
retrieved from an independent costing study conducted by IMS
Health from a third party health care payer perspective in South
Korea. Costs and clinical beneﬁts were discounted at 5% per
annum. Sensitivity analyses were performed. RESULTS: The
results indicated that acarbose treatment was associated with
improvements in discounted life expectancy (0.03 years) and
decreased lifetime costs (South Korean Won 229,000 or €182 per
patient) compared to placebo. Thus, acarbose was dominant (life
and cost saving) to placebo. Furthermore, the proportion of
patients that developed diabetes was 45.6% for acarbose and
53.8% for placebo and diabetes free survival was 4.31 and 4.12
years for acarbose and placebo, respectively. CONCLUSION:
This study demonstrated that acarbose versus placebo was asso-
ciated with improvements in life expectancy and a reduction in
diabetes related costs, and is likely to represent excellent value
for money in patients with IGT in the South Korean setting, from
a third party health care payer perspective.
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OBJECTIVES: This study sought to evaluate the cost utility of
insulin glargine in the UK for people with Type 1 diabetes mel-
litus (T1DM) using observational data in patients switching from
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